LGC and AKOS combine to offer expanded drug development services
LGC has formed a strategic alliance with AKOS, the UK-based specialist drug development and regulatory affairs consultancy company, that will enable both parties to expand the range of services they offer to drug discovery companies. AKOS specialises in leading clients from drug discovery through the development process, and has a strong track record of enabling organisations to achieve their strategic aims, including onward sale or licensing, through to marketing authorisation. LGC offers a wide range of analytical services and instrumentation that are applied across the drug development cycle from early phase discovery through to clinical trial. Through this alliance clients will benefit from the best in advice and services that will enhance the development and valuation of new products.
Most read news
Topics
Organizations
Other news from the department business & finance

Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.